Views Expressed Disclaimer:

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

The FTSE 100 is trading in mixed territory today, but a group of standout companies are moving decisively higher, supported by earnings surprises, structural industry tailwinds, and shifting investor expectations. From healthcare technology to copper mining and defensive utilities, each of these nine stocks is advancing for different reasons — offering investors a broad view of where capital is flowing in the UK market right now.

Below is a comprehensive analysis of each company, including the catalysts behind today’s share price move, long-term investment potential, analyst sentiment, and key risks investors should monitor.

Source: Kalkine Group

1. ConvaTec Group (CTEC) — Shares Jump Over 10%

What’s Driving the Surge

ConvaTec is the top performer on the FTSE 100 today after reporting stronger-than-expected full-year results and upgrading its long-term growth outlook. The medical technology company now anticipates organic revenue growth of 6–8% annually from 2027 onward, compared with its prior 5–7% forecast. While the numerical change may appear modest, for a healthcare company seeking to rebuild credibility with investors, the upgrade was highly meaningful.

The results reinforced confidence that ConvaTec’s turnaround strategy is gaining traction, particularly in its higher-margin product segments.

Financial Performance Highlights

The company delivered solid growth across its key divisions:

  • Continence Care posted the fastest expansion, supported by increased adoption of catheter products and demographic demand from ageing populations.
  • Ostomy Care, the core business, benefited from product innovation and expansion in emerging markets.
  • Advanced Wound Care grew steadily when excluding the underperforming InnovaMatrix product line.

Margins improved due to operational efficiency initiatives under the company’s transformation programme, and free cash flow strengthened enough to support both share buybacks and a double-digit dividend increase.

InnovaMatrix Write-Down: A Manageable Setback

The main negative was an impairment related to reimbursement cuts for InnovaMatrix in the United States. However, investors largely interpreted the write-down as a reset rather than a structural problem. By excluding the product from future growth guidance, management effectively clarified the company’s core earnings trajectory.

Underappreciated Growth Driver: Infusion Care

One of the most promising areas is the Infusion Care segment, which is expanding beyond diabetes into other chronic disease therapies. Diversification into non-diabetes treatments reduces competitive pressure and could support sustained above-market growth.

Investment Outlook

With improving margins, upgraded growth targets, and strong analyst support, ConvaTec’s rally may represent a re-rating rather than a short-term spike. Regulatory reimbursement risk and currency exposure remain key uncertainties, but fundamentals are strengthening.

2. Croda International (CRDA) — Up Nearly 8%

Recovery Momentum Builds

Croda is climbing after reporting better-than-expected second-half results, suggesting that the multi-year destocking cycle affecting specialty chemicals demand is ending. Investors have been waiting for evidence that volumes were stabilising, and recent results provided that confirmation.

From Boom to Bust — and Back

The company experienced extraordinary demand during the pandemic period, followed by a sharp contraction as customers reduced inventories. Now, purchasing patterns are normalising across both Consumer Care and Life Sciences, allowing Croda to return to growth.

Competitive Advantages

Croda operates in niche markets where switching suppliers is difficult due to regulatory approvals and formulation requirements. This creates strong pricing power and customer retention, supporting long-term margins.

Heavy investment in research and development also supports innovation-led growth, particularly in sustainable ingredients and pharmaceutical delivery technologies.

Valuation Debate

Croda trades at a premium to the broader chemicals sector. Supporters argue the premium reflects structural advantages, while critics question whether earnings recovery will justify the valuation. The stock’s trajectory will depend heavily on how quickly demand rebounds to pre-downturn levels.

3. Antofagasta (ANTO) — Supported by Copper Strength

Record Profitability Driving Investor Interest

Antofagasta is rising as investors continue reacting to exceptional annual results driven by higher copper prices and disciplined cost control. Profit margins reached industry-leading levels, highlighting the company’s operational efficiency.

Copper’s Structural Bull Case

The long-term investment thesis rests on global electrification trends:

  • Electric vehicles require significantly more copper than conventional vehicles.
  • Renewable energy systems depend heavily on copper infrastructure.
  • Data centres and AI infrastructure demand large quantities of electrical materials.

Supply constraints — including declining ore grades and permitting challenges — reinforce the bullish outlook.

Growth Projects

Major expansion projects at Los Pelambres and Centinela are expected to increase production significantly over the coming years, supporting medium-term earnings growth.

Risks

Commodity price volatility and political risk in Chile remain the primary uncertainties, but for investors seeking exposure to a potential copper supercycle, Antofagasta remains a high-quality option.

4. Halma (HLMA) — Quality Compounder Near Highs

Consistent Growth Model

Halma continues to attract investors due to its long record of compounding earnings through acquisitions and organic growth. The company operates a decentralised structure of niche technology businesses focused on safety, health, and environmental solutions.

AI-Related Tailwinds

Strong demand for photonics products used in semiconductor manufacturing — partly driven by AI investment — has accelerated growth and prompted upgraded guidance.

Premium Valuation

Halma trades at one of the highest valuation multiples in the FTSE 100, reflecting its exceptional consistency. The key question for investors is whether growth can remain strong enough to justify the premium.

5. Hikma Pharmaceuticals (HIK) — Pre-Earnings Optimism

Investors Positioning Ahead of Results

Shares are edging higher before the company’s earnings release, supported by expectations that recent momentum in its Injectables division will continue.

Strong Competitive Position

Manufacturing sterile injectable medicines involves complex regulatory requirements, creating barriers to entry and supporting higher margins compared with traditional generics.

Biosimilars as Future Growth

Recent launches of biosimilar treatments targeting blockbuster drugs could represent a significant growth opportunity, helping Hikma move up the pharmaceutical value chain.

Valuation Opportunity

The stock trades at a relatively low earnings multiple compared with peers, suggesting potential upside if execution remains strong.

6. Ashtead Group (AHT) — Structural Growth Story Intact

Market Looking Beyond Cyclical Weakness

Ashtead is advancing despite a softer construction environment, as investors focus on its long-term growth drivers and strong cash generation.

Equipment Rental Tailwinds

The shift from equipment ownership to rental continues to support industry expansion. Infrastructure investment, energy projects, and data centre construction provide additional demand drivers.

NYSE Listing Catalyst

The planned primary listing in New York could broaden the investor base and potentially lead to valuation re-rating.

Risks

Economic cycles remain the biggest uncertainty, given the company’s exposure to construction activity.

7. Kingfisher (KGF) — Home Improvement Recovery

Improving Consumer Trends

Kingfisher is benefiting from stabilising housing markets and improved consumer confidence, leading to stronger sales momentum and profit upgrades.

Key Brands Driving Growth

B&Q and Screwfix are performing particularly well, with strong trade customer demand and digital sales growth supporting performance.

France: The Swing Factor

French operations remain the main variable in the investment story. A sustained recovery there could significantly boost profitability.

8. DCC (DCC) — Defensive Compounder Appeal

Steady Business Model Attracting Investors

DCC’s diversified distribution operations in energy and technology provide stable cash flows, making it attractive during uncertain markets.

Acquisition-Driven Growth

The company has built its track record through disciplined acquisitions, particularly in fragmented markets where consolidation creates value.

Energy Transition Challenge

The shift away from fossil fuels presents long-term risks, but also opportunities if the company successfully pivots toward renewable energy solutions.

9. Severn Trent (SVT) — Defensive Utility Demand

Income and Stability Drawing Buyers

Utility stocks are gaining interest as investors seek defensive assets with predictable dividends. Severn Trent’s regulated revenue model provides strong earnings visibility.

Major Investment Cycle

The upcoming regulatory period involves substantial infrastructure spending, which should expand the company’s asset base and support future revenue growth.

Dividend Strength

Reliable payouts remain a core attraction, particularly for income-focused investors.

Final Thoughts: Should Investors Buy These FTSE 100 Winners?

Today’s rising FTSE 100 stocks reflect several broader market themes:

  • Healthcare innovation and demographic demand (ConvaTec, Hikma)
  • Structural commodity trends (Antofagasta)
  • High-quality compounders with pricing power (Halma, Croda)
  • Cyclical recovery opportunities (Ashtead, Kingfisher)
  • Defensive income plays (DCC, Severn Trent)

Whether they are worth buying depends on investor goals:

  • Growth investors may favour ConvaTec, Halma, or Antofagasta.
  • Value investors could see opportunity in Hikma or Kingfisher.
  • Income-focused investors may prefer Severn Trent or DCC.

The diversity of sectors among today’s gainers suggests that market leadership is broadening — often a healthy sign for equity markets overall.